Suppr超能文献

大麻/大麻素的药用应用。

Medicinal applications of cannabis/cannabinoids.

机构信息

Medical Research Institute of New Zealand, Private Bag 7902, Wellington 6242, New Zealand.

University of Otago, Department of Psychological Medicine, PO Box 7343, Wellington 6242, New Zealand; Capital and Coast District Health Board, Private Bag, 7902, Wellington 6242, New Zealand.

出版信息

Curr Opin Psychol. 2021 Apr;38:1-10. doi: 10.1016/j.copsyc.2020.06.002. Epub 2020 Jun 20.

Abstract

Regulatory approvals for Epidiolex (purified cannabidiol) in the treatment of childhood drug resistant epilepsy have set a precedent for the use of cannabinoids as a prescribed medicine. Two common reasons cited for the use and prescription of cannabis-based products are pain and insomnia. Unlike drug resistant epilepsy, the level of evidence of efficacy in pain is poorly developed. The lowest quality trials with the greatest methodological shortcomings suggest some benefit, a level of evidence that is inconsistent with widespread prescribing. The evidence in insomnia is scant. Ongoing trial development and critical review of the literature should not be overshadowed by increasing permissiveness towards cannabis use and anecdotal reports of efficacy.

摘要

Epidiolex(纯化大麻二酚)获得监管批准用于治疗儿童耐药性癫痫,为将大麻素作为处方药使用开创了先例。使用和开处基于大麻的产品的两个常见原因是疼痛和失眠。与耐药性癫痫不同,疼痛疗效的证据水平尚未充分发展。质量最低、方法学缺陷最大的试验表明有一些益处,这种证据水平与广泛开处方不一致。失眠方面的证据很少。不断进行的试验开发和对文献的严格审查不应因对大麻使用的日益宽容和疗效的传闻报告而黯然失色。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验